ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary ADAR-mediated Axiomer™ RNA editing technology ...

Data from the RestorAATion-2 clinical trial of WVE-006 (GalNAc-RNA editing), including new data from the 400 mg multidose cohort and 600 mg ...

Wave Life Sciences (NASDAQ:WVE) highlighted upcoming clinical catalysts across its obesity and RNA editing programs during a ...

Emerging research suggests reversible RNA editing mechanisms may influence heart disease biology while opening new avenues for biomarkers and next-generation cardiovascular therapies. Review: RNA ...

Parkinson's disease (PD) is a neurodegenerative disorder in which the α-synuclein protein abnormally aggregates within brain cells, causing neuronal damage. Through international collaboration, ...

Q4 2025 earnings call highlights: obesity WVE-007 data, RNA editing WVE-006 updates, GSK milestones, runway—read now.

ProQR Therapeutics is advancing its Axiomer ADAR-mediated RNA editing pipeline, aiming to file a Clinical Trial Application for its lead program AX-0810, targeting NTCP for cholestatic diseases, by Q2 ...

A research team led by Rice's Yang Gao has uncovered new insights into the molecular mechanisms of ADAR1. ADAR1 converts adenosine to inosine in double-stranded RNA, a process essential for preventing ...

Eli Lilly And Co (NYSE:LLY) on Thursday entered into a strategic global research collaboration and licensing agreement with Rznomics Inc., a South Korea-based biopharmaceutical company specializing in ...

All starting from the same DNA, neurons ultimately take on individual characteristics in the brain and body. Differences in which genes they transcribe into RNA help determine which type of neuron ...